Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-08

AUTHORS

Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht, Isabel Sevilla, Frédéric Forget, Gianpiero Fasola, Jean-Luc Canon, Xuesong Guan, Gaston Demonty, Lee S. Schwartzberg

ABSTRACT

PURPOSE: To report planned final overall (OS) and progression-free survival (PFS) analyses from the phase II PEAK trial (NCT00819780). METHODS: Patients with previously untreated, KRAS exon 2 wild-type (WT) metastatic colorectal cancer (mCRC) were randomised to mFOLFOX6 plus panitumumab or bevacizumab. The primary endpoint was PFS; secondary endpoints included OS, objective response rate, duration of response (DoR), time to response, resection and safety. Treatment effect by tumour RAS status was a prespecified objective. Exploratory analyses included early tumour shrinkage (ETS) and depth of response (DpR). RESULTS: One hundred seventy patients had RAS WT and 156 had RAS WT/BRAF WT mCRC. Median PFS was longer for panitumumab versus bevacizumab in the RAS WT (12.8 vs 10.1 months; hazard ratio (HR) = 0.68 [95% confidence intervals (CI) = 0.48-0.96]; p = 0.029) and RAS WT/BRAF WT (13.1 vs 10.1 months; HR = 0.61 [95% CI = 0.42-0.88]; p = 0.0075) populations. Median OS (68% OS events) for panitumumab versus bevacizumab was 36.9 versus 28.9 months (HR = 0.76 [95% CI = 0.53-1.11]; p = 0.15) and 41.3 versus 28.9 months (HR = 0.70 [95% CI = 0.48-1.04]; p = 0.08), in the RAS WT and RAS WT/BRAF WT populations, respectively. Median DoR (11.4 vs 9.0 months; HR = 0.59 [95% CI = 0.39-0.88]; p = 0.011) and DpR (65.0 vs 46.3%; p = 0.0018) were improved in the panitumumab group. More panitumumab patients experienced ≥30% ETS at week 8 (64 vs 45%; p = 0.052); ETS was associated with improved PFS/OS. No new safety signals occurred. CONCLUSIONS: First-line panitumumab + mFOLFOX6 increases PFS versus bevacizumab + mFOLFOX6 in patients with RAS WT mCRC. More... »

PAGES

1179-1190

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00384-017-2800-1

DOI

http://dx.doi.org/10.1007/s00384-017-2800-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084939531

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28424871


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Demography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Panitumumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Marqu\u00e9s de Valdecilla University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411325.0", 
          "name": [
            "Hospital Universitario Marqu\u00e9s de Valdecilla, Av. de Valdecilla, 39008, Santander, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rivera", 
        "givenName": "Fernando", 
        "id": "sg:person.01164142067.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164142067.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St\u00e4dtisches Klinikum M\u00fcnchen", 
          "id": "https://www.grid.ac/institutes/grid.419595.5", 
          "name": [
            "St\u00e4dtisches Klinikum M\u00fcnchen, Klinikum Neuperlach, Munich, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Karthaus", 
        "givenName": "Meinolf", 
        "id": "sg:person.0740542517.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740542517.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California Los Angeles", 
          "id": "https://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hecht", 
        "givenName": "J. Randolph", 
        "id": "sg:person.01021445032.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021445032.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Cl\u00ednico Universitario Virgen de la Victoria", 
          "id": "https://www.grid.ac/institutes/grid.411062.0", 
          "name": [
            "Virgen de la Victoria University Hospital, Malaga, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sevilla", 
        "givenName": "Isabel", 
        "id": "sg:person.01223401475.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223401475.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Centre Hospitalier de l\u2019Ardenne, Libramont, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Forget", 
        "givenName": "Fr\u00e9d\u00e9ric", 
        "id": "sg:person.01106264777.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106264777.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Santa Maria della Misericordia di Udine", 
          "id": "https://www.grid.ac/institutes/grid.411492.b", 
          "name": [
            "University Hospital Santa Maria della Misericordia, Udine, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fasola", 
        "givenName": "Gianpiero", 
        "id": "sg:person.01110224311.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110224311.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Grand Charleroi Hospital", 
          "id": "https://www.grid.ac/institutes/grid.490655.b", 
          "name": [
            "Grand H\u00f4pital de Charleroi, Charleroi, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Canon", 
        "givenName": "Jean-Luc", 
        "id": "sg:person.01036415127.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036415127.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., Biostatistics, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guan", 
        "givenName": "Xuesong", 
        "id": "sg:person.013734635611.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013734635611.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.476152.3", 
          "name": [
            "Medical Development \u2013 Oncology, Amgen (Europe) GmbH, Zug, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Demonty", 
        "givenName": "Gaston", 
        "id": "sg:person.015702065145.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015702065145.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "West Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.488536.4", 
          "name": [
            "West Clinic, Memphis, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartzberg", 
        "givenName": "Lee S.", 
        "id": "sg:person.01361146223.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361146223.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/mdt165", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003846952"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.53.2473", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014382035"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.42.8532", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017331195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00122-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019437953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2016.07.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022391511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2015.05.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025513820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1403108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025548121"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029291056"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1305275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030588737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70330-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032780345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2015.37", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033419992", 
          "https://doi.org/10.1038/bjc.2015.37"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.61.2887", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036446880"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu193.30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037095042"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038622532"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clcc.2014.12.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041890021"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2015.03.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043928304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2015.06.116", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044772818"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-015-0386-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049007948", 
          "https://doi.org/10.1007/s40265-015-0386-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-015-0386-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049007948", 
          "https://doi.org/10.1007/s40265-015-0386-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-1100-03", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050703391"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14712598.2015.1050375", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067589097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074841716", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079046787", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu438.13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083557932"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-08", 
    "datePublishedReg": "2017-08-01", 
    "description": "PURPOSE: To report planned final overall (OS) and progression-free survival (PFS) analyses from the phase II PEAK trial (NCT00819780).\nMETHODS: Patients with previously untreated, KRAS exon 2 wild-type (WT) metastatic colorectal cancer (mCRC) were randomised to mFOLFOX6 plus panitumumab or bevacizumab. The primary endpoint was PFS; secondary endpoints included OS, objective response rate, duration of response (DoR), time to response, resection and safety. Treatment effect by tumour RAS status was a prespecified objective. Exploratory analyses included early tumour shrinkage (ETS) and depth of response (DpR).\nRESULTS: One hundred seventy patients had RAS WT and 156 had RAS WT/BRAF WT mCRC. Median PFS was longer for panitumumab versus bevacizumab in the RAS WT (12.8 vs 10.1\u00a0months; hazard ratio (HR)\u00a0=\u00a00.68 [95% confidence intervals (CI)\u00a0=\u00a00.48-0.96]; p\u00a0=\u00a00.029) and RAS WT/BRAF WT (13.1 vs 10.1\u00a0months; HR\u00a0=\u00a00.61 [95% CI\u00a0=\u00a00.42-0.88]; p\u00a0=\u00a00.0075) populations. Median OS (68% OS events) for panitumumab versus bevacizumab was 36.9 versus 28.9\u00a0months (HR\u00a0=\u00a00.76 [95% CI\u00a0=\u00a00.53-1.11]; p\u00a0=\u00a00.15) and 41.3 versus 28.9\u00a0months (HR\u00a0=\u00a00.70 [95% CI\u00a0=\u00a00.48-1.04]; p\u00a0=\u00a00.08), in the RAS WT and RAS WT/BRAF WT populations, respectively. Median DoR (11.4 vs 9.0\u00a0months; HR\u00a0=\u00a00.59 [95% CI\u00a0=\u00a00.39-0.88]; p\u00a0=\u00a00.011) and DpR (65.0 vs 46.3%; p\u00a0=\u00a00.0018) were improved in the panitumumab group. More panitumumab patients experienced \u226530% ETS at week 8 (64 vs 45%; p\u00a0=\u00a00.052); ETS was associated with improved PFS/OS. No new safety signals occurred.\nCONCLUSIONS: First-line panitumumab + mFOLFOX6 increases PFS versus bevacizumab + mFOLFOX6 in patients with RAS WT mCRC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00384-017-2800-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096381", 
        "issn": [
          "0179-1958", 
          "1432-1262"
        ], 
        "name": "International Journal of Colorectal Disease", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "name": "Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma", 
    "pagination": "1179-1190", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fb49d68ac66440cbd552e8a52dbd4f4988d74c0a317699105273014bdcd46057"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28424871"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8607899"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00384-017-2800-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084939531"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00384-017-2800-1", 
      "https://app.dimensions.ai/details/publication/pub.1084939531"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113641_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00384-017-2800-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00384-017-2800-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00384-017-2800-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00384-017-2800-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00384-017-2800-1'


 

This table displays all metadata directly associated to this object as RDF triples.

299 TRIPLES      21 PREDICATES      70 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00384-017-2800-1 schema:about N08df224079904fdb8ef7e2666768691b
2 N208557ed4b16404798c5b83e98ba0c42
3 N23ad97d2e55245ada5b2f1acea6f9323
4 N24f7829690934644bcf3a11fc8653766
5 N54db58a1e86f4f25a47f9cac46fe9849
6 N5fba1ed4c41b4dd2b5a7b2315d206e1e
7 N72ec14706c3f49d586d9683ad1d6e3b1
8 N823b9c7949dc46edb1f00e4ca47f2ea2
9 N85cb4d6c36bc4fc7871c72117db6a20b
10 Nbd1bd3c0296b4e52ad88401b7d5ef83c
11 Nbe6aa569dfb44a7e989d95dd8363d028
12 Ncece10f75e1f4433a36a2d41e5fee3ca
13 Nd136a2afe98c4fb1aec273343a154b06
14 Nf0e2e0b2666b4ec5aa99846a113d7c14
15 Nf93ac641ec8c4f2ca6e87ea5c274ab2e
16 Nfd769b0da34443aab2fa66fb6dca157b
17 Nfd8f6253b1784eb8abf0667b23e5ce8d
18 Nfe91abd983a4452d906f875be9851544
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Nad6272407d104bcf88fd18cc1ae17899
22 schema:citation sg:pub.10.1007/s40265-015-0386-x
23 sg:pub.10.1038/bjc.2015.37
24 https://app.dimensions.ai/details/publication/pub.1074841716
25 https://app.dimensions.ai/details/publication/pub.1079046787
26 https://doi.org/10.1016/j.clcc.2014.12.011
27 https://doi.org/10.1016/j.critrevonc.2015.05.016
28 https://doi.org/10.1016/j.ejca.2015.03.026
29 https://doi.org/10.1016/j.ejca.2015.06.116
30 https://doi.org/10.1016/j.ejca.2016.07.019
31 https://doi.org/10.1016/s1470-2045(14)70330-4
32 https://doi.org/10.1016/s1470-2045(15)00122-9
33 https://doi.org/10.1056/nejmoa1305275
34 https://doi.org/10.1056/nejmoa1403108
35 https://doi.org/10.1093/annonc/mdt165
36 https://doi.org/10.1093/annonc/mdu193.30
37 https://doi.org/10.1093/annonc/mdu260
38 https://doi.org/10.1093/annonc/mdu438.13
39 https://doi.org/10.1093/annonc/mdv112
40 https://doi.org/10.1158/1078-0432.ccr-1100-03
41 https://doi.org/10.1200/jco.2012.42.8532
42 https://doi.org/10.1200/jco.2013.53.2473
43 https://doi.org/10.1200/jco.2015.61.2887
44 https://doi.org/10.1517/14712598.2015.1050375
45 schema:datePublished 2017-08
46 schema:datePublishedReg 2017-08-01
47 schema:description PURPOSE: To report planned final overall (OS) and progression-free survival (PFS) analyses from the phase II PEAK trial (NCT00819780). METHODS: Patients with previously untreated, KRAS exon 2 wild-type (WT) metastatic colorectal cancer (mCRC) were randomised to mFOLFOX6 plus panitumumab or bevacizumab. The primary endpoint was PFS; secondary endpoints included OS, objective response rate, duration of response (DoR), time to response, resection and safety. Treatment effect by tumour RAS status was a prespecified objective. Exploratory analyses included early tumour shrinkage (ETS) and depth of response (DpR). RESULTS: One hundred seventy patients had RAS WT and 156 had RAS WT/BRAF WT mCRC. Median PFS was longer for panitumumab versus bevacizumab in the RAS WT (12.8 vs 10.1 months; hazard ratio (HR) = 0.68 [95% confidence intervals (CI) = 0.48-0.96]; p = 0.029) and RAS WT/BRAF WT (13.1 vs 10.1 months; HR = 0.61 [95% CI = 0.42-0.88]; p = 0.0075) populations. Median OS (68% OS events) for panitumumab versus bevacizumab was 36.9 versus 28.9 months (HR = 0.76 [95% CI = 0.53-1.11]; p = 0.15) and 41.3 versus 28.9 months (HR = 0.70 [95% CI = 0.48-1.04]; p = 0.08), in the RAS WT and RAS WT/BRAF WT populations, respectively. Median DoR (11.4 vs 9.0 months; HR = 0.59 [95% CI = 0.39-0.88]; p = 0.011) and DpR (65.0 vs 46.3%; p = 0.0018) were improved in the panitumumab group. More panitumumab patients experienced ≥30% ETS at week 8 (64 vs 45%; p = 0.052); ETS was associated with improved PFS/OS. No new safety signals occurred. CONCLUSIONS: First-line panitumumab + mFOLFOX6 increases PFS versus bevacizumab + mFOLFOX6 in patients with RAS WT mCRC.
48 schema:genre research_article
49 schema:inLanguage en
50 schema:isAccessibleForFree true
51 schema:isPartOf N0841cb95d7854569896bd02a4868c874
52 N9a18b687b3854d9499381ddb87cf256c
53 sg:journal.1096381
54 schema:name Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
55 schema:pagination 1179-1190
56 schema:productId N4c77a6f2399c4fb5919728b5192640d6
57 N5b716ec9490e45aa9739a429b1a94c7b
58 N7d40042f23fb4554b71aac3c8e1c5581
59 Nc5781d604a49494481a5ffe5a7887ab5
60 Ne95df7b1856d46748b4974fb9b82e210
61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084939531
62 https://doi.org/10.1007/s00384-017-2800-1
63 schema:sdDatePublished 2019-04-11T10:29
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher N5d598b47730d41eb82c1b6b0ec493cc8
66 schema:url https://link.springer.com/10.1007%2Fs00384-017-2800-1
67 sgo:license sg:explorer/license/
68 sgo:sdDataset articles
69 rdf:type schema:ScholarlyArticle
70 N01758c2a9aa44ba4bcfba82c4a400dfa rdf:first sg:person.01223401475.22
71 rdf:rest Nc04f54932dde41c883ab6d6e89fb225d
72 N0841cb95d7854569896bd02a4868c874 schema:issueNumber 8
73 rdf:type schema:PublicationIssue
74 N08df224079904fdb8ef7e2666768691b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Demography
76 rdf:type schema:DefinedTerm
77 N208557ed4b16404798c5b83e98ba0c42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Middle Aged
79 rdf:type schema:DefinedTerm
80 N23ad97d2e55245ada5b2f1acea6f9323 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Humans
82 rdf:type schema:DefinedTerm
83 N24f7829690934644bcf3a11fc8653766 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Aged
85 rdf:type schema:DefinedTerm
86 N25a16cc15ef04226ac549b9e7e557e86 rdf:first sg:person.013734635611.44
87 rdf:rest N42772e7c14a04ac69da78f278e27d91a
88 N42772e7c14a04ac69da78f278e27d91a rdf:first sg:person.015702065145.43
89 rdf:rest N44463d9cd3b442a1a9bcba6d37476f61
90 N44463d9cd3b442a1a9bcba6d37476f61 rdf:first sg:person.01361146223.03
91 rdf:rest rdf:nil
92 N48cdfcf7fc6c401596a7e73c0c3a98b8 schema:name Centre Hospitalier de l’Ardenne, Libramont, Belgium
93 rdf:type schema:Organization
94 N4c77a6f2399c4fb5919728b5192640d6 schema:name doi
95 schema:value 10.1007/s00384-017-2800-1
96 rdf:type schema:PropertyValue
97 N54db58a1e86f4f25a47f9cac46fe9849 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Kaplan-Meier Estimate
99 rdf:type schema:DefinedTerm
100 N5b716ec9490e45aa9739a429b1a94c7b schema:name dimensions_id
101 schema:value pub.1084939531
102 rdf:type schema:PropertyValue
103 N5d598b47730d41eb82c1b6b0ec493cc8 schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 N5fba1ed4c41b4dd2b5a7b2315d206e1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Antibodies, Monoclonal
107 rdf:type schema:DefinedTerm
108 N72ec14706c3f49d586d9683ad1d6e3b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Male
110 rdf:type schema:DefinedTerm
111 N7d40042f23fb4554b71aac3c8e1c5581 schema:name readcube_id
112 schema:value fb49d68ac66440cbd552e8a52dbd4f4988d74c0a317699105273014bdcd46057
113 rdf:type schema:PropertyValue
114 N823b9c7949dc46edb1f00e4ca47f2ea2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Adult
116 rdf:type schema:DefinedTerm
117 N85cb4d6c36bc4fc7871c72117db6a20b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Panitumumab
119 rdf:type schema:DefinedTerm
120 N8641534bbaed4b22bda4dde5d0b9be1b rdf:first sg:person.0740542517.29
121 rdf:rest Ne029831762f74779989b973aa5c53ac7
122 N9a18b687b3854d9499381ddb87cf256c schema:volumeNumber 32
123 rdf:type schema:PublicationVolume
124 Nad6272407d104bcf88fd18cc1ae17899 rdf:first sg:person.01164142067.57
125 rdf:rest N8641534bbaed4b22bda4dde5d0b9be1b
126 Nbd1bd3c0296b4e52ad88401b7d5ef83c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Antineoplastic Combined Chemotherapy Protocols
128 rdf:type schema:DefinedTerm
129 Nbe6aa569dfb44a7e989d95dd8363d028 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Bevacizumab
131 rdf:type schema:DefinedTerm
132 Nc04f54932dde41c883ab6d6e89fb225d rdf:first sg:person.01106264777.28
133 rdf:rest Nc8740c36025f4967bc952e60d0c5fb87
134 Nc5781d604a49494481a5ffe5a7887ab5 schema:name pubmed_id
135 schema:value 28424871
136 rdf:type schema:PropertyValue
137 Nc8740c36025f4967bc952e60d0c5fb87 rdf:first sg:person.01110224311.36
138 rdf:rest Nd24d476ead1e49cb981e56d085ed11bf
139 Ncece10f75e1f4433a36a2d41e5fee3ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Aged, 80 and over
141 rdf:type schema:DefinedTerm
142 Nd136a2afe98c4fb1aec273343a154b06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Female
144 rdf:type schema:DefinedTerm
145 Nd24d476ead1e49cb981e56d085ed11bf rdf:first sg:person.01036415127.22
146 rdf:rest N25a16cc15ef04226ac549b9e7e557e86
147 Ne029831762f74779989b973aa5c53ac7 rdf:first sg:person.01021445032.82
148 rdf:rest N01758c2a9aa44ba4bcfba82c4a400dfa
149 Ne95df7b1856d46748b4974fb9b82e210 schema:name nlm_unique_id
150 schema:value 8607899
151 rdf:type schema:PropertyValue
152 Nf0e2e0b2666b4ec5aa99846a113d7c14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Survival Analysis
154 rdf:type schema:DefinedTerm
155 Nf93ac641ec8c4f2ca6e87ea5c274ab2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Young Adult
157 rdf:type schema:DefinedTerm
158 Nfd769b0da34443aab2fa66fb6dca157b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Colorectal Neoplasms
160 rdf:type schema:DefinedTerm
161 Nfd8f6253b1784eb8abf0667b23e5ce8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Disease-Free Survival
163 rdf:type schema:DefinedTerm
164 Nfe91abd983a4452d906f875be9851544 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Treatment Outcome
166 rdf:type schema:DefinedTerm
167 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
168 schema:name Medical and Health Sciences
169 rdf:type schema:DefinedTerm
170 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
171 schema:name Oncology and Carcinogenesis
172 rdf:type schema:DefinedTerm
173 sg:journal.1096381 schema:issn 0179-1958
174 1432-1262
175 schema:name International Journal of Colorectal Disease
176 rdf:type schema:Periodical
177 sg:person.01021445032.82 schema:affiliation https://www.grid.ac/institutes/grid.19006.3e
178 schema:familyName Hecht
179 schema:givenName J. Randolph
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021445032.82
181 rdf:type schema:Person
182 sg:person.01036415127.22 schema:affiliation https://www.grid.ac/institutes/grid.490655.b
183 schema:familyName Canon
184 schema:givenName Jean-Luc
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036415127.22
186 rdf:type schema:Person
187 sg:person.01106264777.28 schema:affiliation N48cdfcf7fc6c401596a7e73c0c3a98b8
188 schema:familyName Forget
189 schema:givenName Frédéric
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106264777.28
191 rdf:type schema:Person
192 sg:person.01110224311.36 schema:affiliation https://www.grid.ac/institutes/grid.411492.b
193 schema:familyName Fasola
194 schema:givenName Gianpiero
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110224311.36
196 rdf:type schema:Person
197 sg:person.01164142067.57 schema:affiliation https://www.grid.ac/institutes/grid.411325.0
198 schema:familyName Rivera
199 schema:givenName Fernando
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164142067.57
201 rdf:type schema:Person
202 sg:person.01223401475.22 schema:affiliation https://www.grid.ac/institutes/grid.411062.0
203 schema:familyName Sevilla
204 schema:givenName Isabel
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223401475.22
206 rdf:type schema:Person
207 sg:person.01361146223.03 schema:affiliation https://www.grid.ac/institutes/grid.488536.4
208 schema:familyName Schwartzberg
209 schema:givenName Lee S.
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361146223.03
211 rdf:type schema:Person
212 sg:person.013734635611.44 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
213 schema:familyName Guan
214 schema:givenName Xuesong
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013734635611.44
216 rdf:type schema:Person
217 sg:person.015702065145.43 schema:affiliation https://www.grid.ac/institutes/grid.476152.3
218 schema:familyName Demonty
219 schema:givenName Gaston
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015702065145.43
221 rdf:type schema:Person
222 sg:person.0740542517.29 schema:affiliation https://www.grid.ac/institutes/grid.419595.5
223 schema:familyName Karthaus
224 schema:givenName Meinolf
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740542517.29
226 rdf:type schema:Person
227 sg:pub.10.1007/s40265-015-0386-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1049007948
228 https://doi.org/10.1007/s40265-015-0386-x
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/bjc.2015.37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033419992
231 https://doi.org/10.1038/bjc.2015.37
232 rdf:type schema:CreativeWork
233 https://app.dimensions.ai/details/publication/pub.1074841716 schema:CreativeWork
234 https://app.dimensions.ai/details/publication/pub.1079046787 schema:CreativeWork
235 https://doi.org/10.1016/j.clcc.2014.12.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041890021
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1016/j.critrevonc.2015.05.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025513820
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1016/j.ejca.2015.03.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043928304
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1016/j.ejca.2015.06.116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044772818
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1016/j.ejca.2016.07.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022391511
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1016/s1470-2045(14)70330-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032780345
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1016/s1470-2045(15)00122-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019437953
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1056/nejmoa1305275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030588737
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1056/nejmoa1403108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025548121
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1093/annonc/mdt165 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003846952
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1093/annonc/mdu193.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037095042
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1093/annonc/mdu260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029291056
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1093/annonc/mdu438.13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083557932
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1093/annonc/mdv112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038622532
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1158/1078-0432.ccr-1100-03 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050703391
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1200/jco.2012.42.8532 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017331195
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1200/jco.2013.53.2473 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014382035
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1200/jco.2015.61.2887 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036446880
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1517/14712598.2015.1050375 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067589097
272 rdf:type schema:CreativeWork
273 https://www.grid.ac/institutes/grid.19006.3e schema:alternateName University of California Los Angeles
274 schema:name David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
275 rdf:type schema:Organization
276 https://www.grid.ac/institutes/grid.411062.0 schema:alternateName Hospital Clínico Universitario Virgen de la Victoria
277 schema:name Virgen de la Victoria University Hospital, Malaga, Spain
278 rdf:type schema:Organization
279 https://www.grid.ac/institutes/grid.411325.0 schema:alternateName Marqués de Valdecilla University Hospital
280 schema:name Hospital Universitario Marqués de Valdecilla, Av. de Valdecilla, 39008, Santander, Spain
281 rdf:type schema:Organization
282 https://www.grid.ac/institutes/grid.411492.b schema:alternateName Ospedale Santa Maria della Misericordia di Udine
283 schema:name University Hospital Santa Maria della Misericordia, Udine, Italy
284 rdf:type schema:Organization
285 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
286 schema:name Amgen Inc., Biostatistics, Thousand Oaks, CA, USA
287 rdf:type schema:Organization
288 https://www.grid.ac/institutes/grid.419595.5 schema:alternateName Städtisches Klinikum München
289 schema:name Städtisches Klinikum München, Klinikum Neuperlach, Munich, Germany
290 rdf:type schema:Organization
291 https://www.grid.ac/institutes/grid.476152.3 schema:alternateName Amgen (Switzerland)
292 schema:name Medical Development – Oncology, Amgen (Europe) GmbH, Zug, Switzerland
293 rdf:type schema:Organization
294 https://www.grid.ac/institutes/grid.488536.4 schema:alternateName West Cancer Center
295 schema:name West Clinic, Memphis, TN, USA
296 rdf:type schema:Organization
297 https://www.grid.ac/institutes/grid.490655.b schema:alternateName Grand Charleroi Hospital
298 schema:name Grand Hôpital de Charleroi, Charleroi, Belgium
299 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...